[go: up one dir, main page]

UA100699C2 - Antibody to human cd20 and using thereof for the treatment cd20-mediated disease or condition - Google Patents

Antibody to human cd20 and using thereof for the treatment cd20-mediated disease or condition

Info

Publication number
UA100699C2
UA100699C2 UAA201002186A UAA201002186A UA100699C2 UA 100699 C2 UA100699 C2 UA 100699C2 UA A201002186 A UAA201002186 A UA A201002186A UA A201002186 A UAA201002186 A UA A201002186A UA 100699 C2 UA100699 C2 UA 100699C2
Authority
UA
Ukraine
Prior art keywords
antibody
human
treatment
condition
mediated disease
Prior art date
Application number
UAA201002186A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Джоел Х. Мартин
Ли-Сиень Ван
Шон СТИВЕНС
Эрин М. ЭЛЛИСОН
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Priority claimed from PCT/US2008/071709 external-priority patent/WO2009018411A1/en
Publication of UA100699C2 publication Critical patent/UA100699C2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to human antibody or antigen-binding fragment thereof that specifically binds to human CD20 and is capable of inducing complement dependent cytotoxicity (CDC). The invention further relates to use of antibody or antigen-binding fragment thereof for the treatment of CD20-mediated disease or condition, for example, non-Hodgkin's lymphoma, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, chronic lymphocytic leukemia, and inflammatory diseases.
UAA201002186A 2007-07-31 2008-07-31 Antibody to human cd20 and using thereof for the treatment cd20-mediated disease or condition UA100699C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96281107P 2007-07-31 2007-07-31
PCT/US2008/071709 WO2009018411A1 (en) 2007-07-31 2008-07-31 Human antibodies to human cd20 and method of using thereof

Publications (1)

Publication Number Publication Date
UA100699C2 true UA100699C2 (en) 2013-01-25

Family

ID=51584484

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201002186A UA100699C2 (en) 2007-07-31 2008-07-31 Antibody to human cd20 and using thereof for the treatment cd20-mediated disease or condition

Country Status (1)

Country Link
UA (1) UA100699C2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12030952B2 (en) 2015-10-02 2024-07-09 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use
US12252533B2 (en) 2015-06-24 2025-03-18 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12252533B2 (en) 2015-06-24 2025-03-18 Hoffmann-La Roche Inc. Anti-transferrin receptor antibodies with tailored affinity
US12030952B2 (en) 2015-10-02 2024-07-09 Hoffmann-La Roche Inc. Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

Similar Documents

Publication Publication Date Title
MY147651A (en) Human antibodies to human cd20 and method of using thereof
MY147468A (en) High affinity antibodies to human il-6 receptor
WO2020121195A8 (en) Trem2 antibodies and uses thereof
CR20200467A (en) ANTI-CD25 ANTIBODY AGENTS
HRP20181459T1 (en) Humanized anti-beta7 antagonists and uses thererfor
MX392069B (en) Tl1a antibodies and uses thereof
TW200639182A (en) Antibody variants and uses thereof
UA112434C2 (en) ANTIGENCY BINDING SPECIFICALLY Binds to ALL
PH12015501656B1 (en) Anti-il-33 antibodies and use thereof
MX2021015309A (en) Compositions for the treatment of rheumatoid arthritis and methods of using same.
MX2009013199A (en) Anti-notch1 nrr antibodies and methods using same.
TN2017000010A1 (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use.
UA106194C2 (en) Diagnosis and treatment of cancer using anti-ereg antibody
BR112012021433A2 (en) anti-7 receptor antagonist antibodies and methods.
MY185813A (en) Factor xi antibodies and methods of use
UA92505C2 (en) Anti-cd3 antibody formulations
MX348013B (en) Anti-il-17f antibodies and methods of use thereof.
MA32802B1 (en) Human antibodies with high affinity for il - 4 receptors
MY194084A (en) Interferon beta antibodies and uses thereof
MX2020005364A (en) Anti-ox40 antibodies and uses thereof.
AU2013232386A8 (en) Treatment of multiple sclerosis with anti-CD19 antibody
TW200801038A (en) Immunoglobulins
UA100699C2 (en) Antibody to human cd20 and using thereof for the treatment cd20-mediated disease or condition
MX2020008768A (en) AGENTS ANTI-CD25 ANTIBODIES.
UA97645C2 (en) Antibody which binds human il-6 receptor